BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34773073)

  • 1. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
    McCann JJ; Vasilevskaya IA; McNair C; Gallagher P; Neupane NP; de Leeuw R; Shafi AA; Dylgjeri E; Mandigo AC; Schiewer MJ; Knudsen KE
    Oncogene; 2022 Jan; 41(3):444-458. PubMed ID: 34773073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
    Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
    Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
    Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
    Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties.
    Garg A; Hazra JP; Sannigrahi MK; Rakshit S; Sinha S
    Biophys J; 2020 Feb; 118(3):720-728. PubMed ID: 31952808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
    Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An N
    Uddin MB; Roy KR; Hosain SB; Khiste SK; Hill RA; Jois SD; Zhao Y; Tackett AJ; Liu YY
    Biochem Pharmacol; 2019 Feb; 160():134-145. PubMed ID: 30578766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
    Kamaraj B; Bogaerts A
    PLoS One; 2015; 10(8):e0134638. PubMed ID: 26244575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-R273H Sustains ROS, Pro-Inflammatory Cytokine Release and mTOR Activation While Reducing Autophagy, Mitophagy and UCP2 Expression, Effects Prevented by wtp53.
    Romeo MA; Gilardini Montani MS; Benedetti R; Arena A; D'Orazi G; Cirone M
    Biomolecules; 2021 Feb; 11(3):. PubMed ID: 33668399
    [No Abstract]   [Full Text] [Related]  

  • 10. Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants.
    Pal A; Gonzalez-Malerva L; Eaton S; Xu C; Zhang Y; Grief D; Sakala L; Nwekwo L; Zeng J; Christensen G; Gupta C; Streitwieser E; Singharoy A; Park JG; LaBaer J
    NPJ Breast Cancer; 2023 Sep; 9(1):78. PubMed ID: 37773066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer.
    Barta JA; Pauley K; Kossenkov AV; McMahon SB
    Carcinogenesis; 2020 Mar; 41(1):67-77. PubMed ID: 31067569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
    Prowald A; Cronauer MV; von Klot C; Eilers T; Rinnab L; Herrmann T; Spindler KD; Montenarh M; Jonas U; Burchardt M
    Prostate; 2007 Dec; 67(16):1751-60. PubMed ID: 17929268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties.
    Nakayama M; Hong CP; Oshima H; Sakai E; Kim SJ; Oshima M
    Nat Commun; 2020 May; 11(1):2333. PubMed ID: 32393735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A CD24-p53 axis contributes to African American prostate cancer disparities.
    Liu W; Zhang Y; Wei S; Bae S; Yang WH; Smith GJ; Mohler JL; Fontham ETH; Bensen JT; Sonpavde GP; Chen GY; Liu R; Wang L
    Prostate; 2020 May; 80(8):609-618. PubMed ID: 32168400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
    Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
    BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ID4 regulates transcriptional activity of wild type and mutant p53 via K373 acetylation.
    Morton DJ; Patel D; Joshi J; Hunt A; Knowell AE; Chaudhary J
    Oncotarget; 2017 Jan; 8(2):2536-2549. PubMed ID: 27911860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.
    Zhang W; Yi B; Wang C; Chen D; Bae S; Wei S; Guo RJ; Lu C; Nguyen LL; Yang WH; Lillard JW; Zhang X; Wang L; Liu R
    Clin Cancer Res; 2016 May; 22(10):2545-54. PubMed ID: 26712693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dominant TP53 hotspot mutation in
    Marker DF; Agnihotri S; Amankulor N; Murdoch GH; Pearce TM
    Neurooncol Adv; 2022; 4(1):vdab182. PubMed ID: 35047821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the Etiology of p53-mutated Cancer Cells.
    Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
    J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An
    Malami I; Muhammad A; Etti IC; Waziri PM; Alhassan AM
    EXCLI J; 2017; 16():1276-1287. PubMed ID: 29333130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.